These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
459 related articles for article (PubMed ID: 22050745)
1. Multi-target-directed ligands in Alzheimer's disease treatment. Bajda M; Guzior N; Ignasik M; Malawska B Curr Med Chem; 2011; 18(32):4949-75. PubMed ID: 22050745 [TBL] [Abstract][Full Text] [Related]
2. Novel small molecule therapeutic agents for Alzheimer disease: Focusing on BACE1 and multi-target directed ligands. Iraji A; Khoshneviszadeh M; Firuzi O; Khoshneviszadeh M; Edraki N Bioorg Chem; 2020 Apr; 97():103649. PubMed ID: 32101780 [TBL] [Abstract][Full Text] [Related]
3. Dual-target compounds for Alzheimer's disease: Natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR). Ferreira JPS; Albuquerque HMT; Cardoso SM; Silva AMS; Silva VLM Eur J Med Chem; 2021 Oct; 221():113492. PubMed ID: 33984802 [TBL] [Abstract][Full Text] [Related]
4. A review on flavonoid-based scaffolds as multi-target-directed ligands (MTDLs) for Alzheimer's disease. Jalili-Baleh L; Babaei E; Abdpour S; Nasir Abbas Bukhari S; Foroumadi A; Ramazani A; Sharifzadeh M; Abdollahi M; Khoobi M Eur J Med Chem; 2018 May; 152():570-589. PubMed ID: 29763806 [TBL] [Abstract][Full Text] [Related]
5. Multi-target-directed therapeutic potential of 7-methoxytacrine-adamantylamine heterodimers in the Alzheimer's disease treatment. Gazova Z; Soukup O; Sepsova V; Siposova K; Drtinova L; Jost P; Spilovska K; Korabecny J; Nepovimova E; Fedunova D; Horak M; Kaniakova M; Wang ZJ; Hamouda AK; Kuca K Biochim Biophys Acta Mol Basis Dis; 2017 Feb; 1863(2):607-619. PubMed ID: 27865910 [TBL] [Abstract][Full Text] [Related]
6. Biaryl scaffold-focused virtual screening for anti-aggregatory and neuroprotective effects in Alzheimer's disease. Khalid S; Zahid MA; Ali H; Kim YS; Khan S BMC Neurosci; 2018 Nov; 19(1):74. PubMed ID: 30424732 [TBL] [Abstract][Full Text] [Related]
7. New neurogenic lipoic-based hybrids as innovative Alzheimer's drugs with σ-1 agonism and β-secretase inhibition. Estrada M; Pérez C; Soriano E; Laurini E; Romano M; Pricl S; Morales-García JA; Pérez-Castillo A; Rodríguez-Franco MI Future Med Chem; 2016 Jul; 8(11):1191-207. PubMed ID: 27402296 [TBL] [Abstract][Full Text] [Related]
8. In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer's Disease. Iman K; Mirza MU; Mazhar N; Vanmeert M; Irshad I; Kamal MA CNS Neurol Disord Drug Targets; 2018 Apr; 17(1):54-68. PubMed ID: 29336270 [TBL] [Abstract][Full Text] [Related]
9. [Design of acetylcholinesterase inhibitor for Alzheimer's disease therapy: from multi-binding site inhibitors to multi-target directed ligands]. Yang WC; Sun Q; Yu NX; Zhu XL; Yang GF Yao Xue Xue Bao; 2012 Mar; 47(3):313-21. PubMed ID: 22645754 [TBL] [Abstract][Full Text] [Related]
10. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease. León R; Garcia AG; Marco-Contelles J Med Res Rev; 2013 Jan; 33(1):139-89. PubMed ID: 21793014 [TBL] [Abstract][Full Text] [Related]
11. Changing Paradigm from one Target one Ligand Towards Multi-target Directed Ligand Design for Key Drug Targets of Alzheimer Disease: An Important Role of In Silico Methods in Multi-target Directed Ligands Design. Kumar A; Tiwari A; Sharma A Curr Neuropharmacol; 2018; 16(6):726-739. PubMed ID: 29542413 [TBL] [Abstract][Full Text] [Related]
12. Multitarget Tacrine Hybrids with Neuroprotective Properties to Confront Alzheimer's Disease. Spilovska K; Korabecny J; Nepovimova E; Dolezal R; Mezeiova E; Soukup O; Kuca K Curr Top Med Chem; 2017; 17(9):1006-1026. PubMed ID: 27697055 [TBL] [Abstract][Full Text] [Related]
13. [Multifunctional ligands--a new approach in the search for drugs against multi-factorial diseases]. Wichur T; Malawska B Postepy Hig Med Dosw (Online); 2015 Jan; 69():1423-34. PubMed ID: 27259214 [TBL] [Abstract][Full Text] [Related]
14. Identifying natural compounds as multi-target-directed ligands against Alzheimer's disease: an in silico approach. Ambure P; Bhat J; Puzyn T; Roy K J Biomol Struct Dyn; 2019 Mar; 37(5):1282-1306. PubMed ID: 29578387 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush. Rosini M; Simoni E; Bartolini M; Cavalli A; Ceccarini L; Pascu N; McClymont DW; Tarozzi A; Bolognesi ML; Minarini A; Tumiatti V; Andrisano V; Mellor IR; Melchiorre C J Med Chem; 2008 Aug; 51(15):4381-4. PubMed ID: 18605718 [TBL] [Abstract][Full Text] [Related]
17. Multipotent AChE and BACE-1 inhibitors for the treatment of Alzheimer's disease: Design, synthesis and bio-analysis of 7-amino-1,4-dihydro-2H-isoquilin-3-one derivates. Zhao XJ; Gong DM; Jiang YR; Guo D; Zhu Y; Deng YC Eur J Med Chem; 2017 Sep; 138():738-747. PubMed ID: 28728106 [TBL] [Abstract][Full Text] [Related]
18. Searching for the Multi-Target-Directed Ligands against Alzheimer's disease: discovery of quinoxaline-based hybrid compounds with AChE, H₃R and BACE 1 inhibitory activities. Huang W; Tang L; Shi Y; Huang S; Xu L; Sheng R; Wu P; Li J; Zhou N; Hu Y Bioorg Med Chem; 2011 Dec; 19(23):7158-67. PubMed ID: 22019465 [TBL] [Abstract][Full Text] [Related]
19. Inhibitory activities of major anthraquinones and other constituents from Cassia obtusifolia against β-secretase and cholinesterases. Jung HA; Ali MY; Jung HJ; Jeong HO; Chung HY; Choi JS J Ethnopharmacol; 2016 Sep; 191():152-160. PubMed ID: 27321278 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of quinazolinone-based hydrazones with potential use in Alzheimer's disease. Haghighijoo Z; Firuzi O; Hemmateenejad B; Emami S; Edraki N; Miri R Bioorg Chem; 2017 Oct; 74():126-133. PubMed ID: 28780149 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]